proteinopathies-skin-neurodegenerative-disorders-nct06528964

Migration, Crosslink

📖

proteinopathies-skin-neurodegenerative-disorders-nct06528964

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-proteinopathies-ski

📖 Wiki Page

clinical_trial2765 wordssynced 2026-04-02

Proteinopathies Expression in Skin of Neurodegenerative Disorders (NCT06528964)

Overview

flowchart TD clinical_trials_proteinopathie["proteinopathies-skin-neurodegenerative-disorders"] style clinical_trials_proteinopathie fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_prot_0["Study Details"] clinical_trials_proteinopathie -->|"includes"| clinical_trials_prot_0 style clinical_trials_prot_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_prot_1["Scientific Rationale"] clinical_trials_proteinopathie -->|"includes"| clinical_trials_prot_1 style clinical_trials_prot_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_prot_2["Understanding Proteinopathies"] clinical_trials_proteinopathie -->|"includes"| clinical_trials_prot_2 style clinical_trials_prot_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_prot_3["Rationale for Skin as Biomarker Tissue"] clinical_trials_proteinopathie -->|"includes"| clinical_trials_prot_3 style clinical_trials_prot_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_prot_4["Detectable Proteins in Skin"] clinical_trials_proteinopathie -->|"includes"| clinical_trials_prot_4 style clinical_trials_prot_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_prot_5["Study Objectives"] clinical_trials_proteinopathie -->|"includes"| clinical_trials_prot_5 style clinical_trials_prot_5 fill:#81c784,stroke:#333,color:#000

...

Proteinopathies Expression in Skin of Neurodegenerative Disorders (NCT06528964)

Overview

Mermaid diagram (expand to render)

This study investigates the expression of proteinopathic markers in skin biopsies from patients with neurodegenerative disorders, evaluating their potential as accessible diagnostic and prognostic biomarkers["@nct"]. The trial represents a significant advance in biomarker development for neurodegenerative diseases, offering the potential for minimally invasive,repeatable tissue sampling that could revolutionize diagnosis and monitoring of conditions like Parkinson's disease, Alzheimer's disease, and atypical parkinsonism.

The skin, as the largest organ in the body, contains peripheral nerve endings and various cell types that may reflect central nervous system pathology. This clinical trial builds on a growing body of evidence demonstrating that pathological proteins accumulate not only in the brain but also in peripheral tissues, making skin biopsy a promising source of disease biomarkers["@marchesetti2021"].

Study Details

| Field | Value |
|-------|-------|
| NCT ID | NCT06528964 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | Parkinson's Disease, PSP, MSA, Alzheimer's Disease, FTD |
| Sample Type | Skin punch biopsies |
| Study Design | Case-control, cross-sectional |
| Primary Outcome | Detection rates of protein aggregates |

Scientific Rationale

Understanding Proteinopathies

Proteinopathies are characterized by abnormal aggregation of specific proteins in the nervous system, leading to cellular dysfunction and neurodegeneration. Each disease is associated with distinct pathological proteins[@cheng2018]:

| Disease | Primary Protein | Aggregation Type |
|---------|----------------|------------------|
| Parkinson's Disease | α-Synuclein | Lewy bodies, Lewy neurites |
| Multiple System Atrophy | α-Synuclein | Glial cytoplasmic inclusions |
| Dementia with Lewy Bodies | α-Synuclein | Cortical Lewy bodies |
| Alzheimer's Disease | Tau, Amyloid-β | Neurofibrillary tangles, plaques |
| Progressive Supranuclear Palsy | 4R Tau | Straight filaments |
| Corticobasal Syndrome | 4R Tau | Astrocytic plaques |
| Frontotemporal Dementia | TDP-43, FUS, Tau | Variety of inclusions |
| Amyotrophic Lateral Sclerosis | TDP-43 | Motor neuron inclusions |

Rationale for Skin as Biomarker Tissue

The use of skin as a source of biomarkers offers several distinct advantages over traditional approaches such as cerebrospinal fluid (CSF) sampling or brain imaging[@wang2019][@doppler2014]:

Practical Advantages

Minimally Invasive: Skin punch biopsies require only local anesthesia and leave minimal scars

Repeatable Sampling: Can be performed repeatedly for longitudinal monitoring

Accessible Locations: Easily reachable areas (e.g., ankle, thigh) provide adequate tissue

Standardized Procedures: Established methodology allows for consistent sampling

Cost-Effective: Significantly less expensive than neuroimaging or CSF collection

Biological Rationale

Peripheral Nervous System Involvement: Skin contains small nerve fibers that may show early pathological changes

Autonomic Nerves: Autonomic nerve fibers in skin are affected in synucleinopathies

Dermal Fibroblasts: May reflect cellular pathology present in neurons[@peled2021]

Systemic Protein Aggregation: Evidence suggests protein aggregates accumulate in peripheral tissues

Comparison with Other Biomarker Sources

| Source | Advantages | Disadvantages |
|--------|------------|---------------|
| CSF | Direct access to CNS | Invasive, requires lumbar puncture |
| Blood | Easy collection | Biomarker levels often low |
| Skin | Minimally invasive, repeatable | Less direct CNS reflection |
| Imaging | Direct visualization | Expensive, limited availability |

Detectable Proteins in Skin

Skin biopsies can be analyzed for multiple pathological proteins[@khatri2021]:

Alpha-Synuclein

Phosphorylated α-synuclein (pSer129): The most specific marker for synucleinopathies
Total α-synuclein: Measures overall protein levels
Oligomeric α-synuclein: Potentially more toxic species

Phosphorylated α-synuclein at Ser129 is particularly valuable because:

It constitutes the majority of pathological inclusions in PD and MSA
It is rarely present in healthy individuals
Detection methods have high sensitivity and specificity

Tau Protein

Phosphorylated tau (p-tau181, p-tau217, p-tau396/404): Pathological forms
Total tau: Marker of neuronal injury
3R/4R tau isoforms:区分不同tauopathy

Tau pathology in skin has been documented in AD and PSP[@peng2018][@stember2022]:

Hyperphosphorylated tau detected in dermal nerve fibers
Potential for distinguishing 3R+4R (AD) from 4R (PSP) tauopathies

TDP-43

Phosphorylated TDP-43: Pathological form in ALS and FTD
C-terminal fragments: Characteristic of FTD/ALS

TDP-43 pathology is a hallmark of ALS and most forms of FTD[@gibbs2019]:

Detection in skin provides less invasive alternative to nerve biopsy
May aid in differential diagnosis

Amyloid-Beta

Aβ40, Aβ42 peptides: Soluble forms
Oligomeric Aβ: Toxic species

Amyloid deposition in skin has been explored as a peripheral biomarker for AD.

Study Objectives

Primary Endpoints

Detection Rates: Determine frequency of pathological protein detection in skin

pSer129 α-synuclein in synucleinopathies
Phosphorylated tau in tauopathies
TDP-43 in FTD/ALS

Diagnostic Correlation: Compare skin findings with clinical diagnosis

Sensitivity and specificity calculations
Positive and negative predictive values

Disease-Specific Patterns: Characterize detection patterns across disease groups

Distribution within skin layers
Comparison between disease subtypes

Secondary Endpoints

Disease Severity Correlation: Relationship between protein burden and clinical measures

UPDRS for Parkinson's disease
PSP Rating Scale for PSP
MMSE/MoCA for cognitive assessment

Biomarker Comparison: Correlation with established biomarkers

CSF α-synuclein, tau, β-amyloid
Neurofilament light chain (NfL) in blood

Differential Diagnosis Utility: Value in distinguishing between conditions

PD vs. MSA vs. DLB
AD vs. FTD
PSP vs. CBS

Exploratory Objectives

Longitudinal Changes: Track changes over disease progression

Treatment Response: Correlation with therapeutic interventions

Preclinical Detection: Examine at-risk individuals (e.g., REM sleep behavior disorder)

Study Design

Sample Collection Protocol

| Parameter | Specification |
|-----------|---------------|
| Biopsy Sites | Ankle (lateral malleolus), thigh (proximal) |
| Punch Size | 3-5 mm diameter |
| Anesthesia | 1% lidocaine, local |
| Processing | Fresh frozen and formalin-fixed |
| Storage | -80°C for frozen, formalin for fixed |

Immunohistochemistry Analysis

The primary analytical approach involves immunohistochemistry using antibodies specific to pathological proteins:

α-Synuclein Detection

Anti-pSer129 antibody (primary)
Fluorescent secondary antibodies
Confocal microscopy visualization

Tau Detection

Multiple phosphorylation-specific antibodies
Tau isoform-specific antibodies (3R vs. 4R)

TDP-43 Detection

C-terminal specific antibodies
Phospho-specific antibodies

Quantification Methods

Protein aggregate burden is quantified using:

Percentage of positive nerve fibers
Intensity scoring
Automated image analysis
Biochemical assays (Western blot, ELISA)

Clinical Applications

Diagnostic Utility

Skin biopsy could transform neurodegenerative disease diagnosis in several ways[@beach2018][@shtein2023]:

Antemortem Confirmation: Provide pathological confirmation of clinical diagnosis

Differential Diagnosis: Aid in distinguishing between clinically similar conditions

Early Detection: Identify pathology before clinical symptoms manifest

Risk Stratification: Guide prognosis in at-risk individuals

Disease Monitoring

Longitudinal skin biopsy could serve as a biomarker for disease progression[@carlon2020]:

Treatment Response: Monitor effects of disease-modifying therapies

Progression Tracking: Objective measure of pathology accumulation

Clinical Trial Endpoint: Surrogate marker for therapeutic efficacy

Comparison of Conditions

| Condition | pSer129-αSyn | p-Tau | TDP-43 |
|------------|--------------|-------|--------|
| Parkinson's Disease | +++ | - | - |
| MSA | +++ | - | - |
| DLB | ++ | - | - |
| Alzheimer's Disease | - | +++ | - |
| PSP | - | +++ | - |
| FTD | - | +/- | +++ |
| ALS | - | - | +++ |

Relevant Disease Background

Parkinson's Disease

PD is characterized by progressive dopaminergic neuron loss in the substantia nigra, accompanied by widespread α-synuclein pathology throughout the nervous system. The presence of pSer129 α-synuclein in skin provides a peripheral marker of this widespread pathology[@doppler2014][@donadio2022].

Clinical features:

Resting tremor, bradykinesia, rigidity
Non-motor symptoms (sleep disturbance, constipation, hyposmia)
Progressive disease course over decades

Progressive Supranuclear Palsy

PSP is a 4R tauopathy characterized by:

Accumulation of hyperphosphorylated tau in neurons and glia
Distinct pathological patterns from AD
4R tau isoform predominance

Clinical features:

Vertical supranuclear gaze palsy
Postural instability with falls
Axial rigidity and bradykinesia

Multiple System Atrophy

MSA is another synucleinopathy with:

α-Synuclein glial cytoplasmic inclusions
Autonomic dysfunction prominent
Poor levodopa response

Alzheimer's Disease

AD features:

Amyloid-beta plaques and tau neurofibrillary tangles
Progressive cognitive decline
Default mode network disruption

Frontotemporal Dementia

FTD spectrum:

Behavioral variant FTD
Primary progressive aphasia
FTD with motor neuron disease

TDP-43 pathology in most cases, tau in some.

Methodology Considerations

Technical Challenges

Sensitivity: Low levels of protein in skin require sensitive detection methods

Standardization: Sampling and processing protocols must be consistent

Interpretation: Normal age-related changes vs. pathological findings

Quantification: Developing reliable quantitative measures

Quality Control Measures

Use of standardized antibodies
Inclusion of positive and negative controls
Blinded assessment
Inter-assay and inter-rater reliability

Expected Findings and Implications

Anticipated Results

High Detection Rates: Significant pSer129 detection in synucleinopathies

Disease-Specific Patterns: Distinct patterns across conditions

Clinical Correlation: Correlation with disease severity

Comparison with CSF: Similar or complementary information to CSF biomarkers

Clinical Implications

If successful, skin biopsy could provide:

Diagnostic Confirmation: Objective pathological evidence
Biomarker for Treatment Response: Monitor therapeutic effects
Disease Progression Marker: Track pathology accumulation
Screening Tool: Early detection in at-risk populations

Research Applications

The ability to repeatedly sample tissue would enable:

Mechanistic Studies: Understanding peripheral pathology
Therapeutic Development: biomarker for clinical trials
Longitudinal Studies: Disease progression monitoring
Family Studies: At-risk individual assessment

Cross-References

[Tau Biomarkers](/biomarkers/tau-biomarkers)
[Alpha-Synuclein Pathology](/proteins/alpha-synuclein)
[Skin Biopsy Biomarkers](/diagnostics/skin-biopsy-biomarkers)
[PSP Diagnosis](/diseases/progressive-supranuclear-palsy-diagnosis)
[Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
[CSF Biomarkers](/diagnostics/csf-biomarkers)
[Dopamine Transporter Imaging](/diagnostics/dat-scan)
[Skin Biopsy for Small Fiber Neuropathy](/diagnostics/skin-biopsy-small-fiber)

[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation)
[Tau Pathology Mechanisms](/mechanisms/tau-pathology)
[TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
[Prion-Like Propagation](/mechanisms/prion-like-protein-spreading)
[Protein Quality Control](/mechanisms/ubiquitin-proteasome-system)

[CSF Biomarkers](/diagnostics/csf-biomarkers)
[Dopamine Transporter Imaging](/diagnostics/dat-scan)
[Skin Biopsy for Small Fiber Neuropathy](/diagnostics/skin-biopsy-small-fiber)
[MRI Neuroimaging](/diagnostics/mri-neurodegeneration)

Technical Methodology Advances

Sample Processing Innovations

Recent advances in skin biopsy processing have improved detection sensitivity:

Cryosectioning Techniques:

Optimal section thickness (8-12 μm)
Temperature-controlled sectioning
Prevention of antigen diffusion

Antigen Retrieval Methods:

Heat-induced epitope retrieval
Enzymatic digestion protocols
Optimized for different proteins

Detection Amplification:

Tyramide signal amplification
Gold nanoparticle labeling
Super-resolution microscopy

Quantitative Analysis Approaches

Standardized quantification methods improve reproducibility:

Image Analysis Software:

Automated nerve fiber detection
Intensity measurement algorithms
Colocalization analysis tools

Bias Correction:

Background subtraction methods
Normalization to control samples
Inter-batch calibration

Quality Metrics:

Signal-to-noise ratios
Coefficient of variation
Inter-rater reliability measures

Clinical Integration and Interpretation

Diagnostic Algorithm Development

Standardized interpretation criteria enhance clinical utility:

Positive Result Criteria:

pSer129 detection in >1 nerve fiber
Consistent with clinical diagnosis
Adequate sample quality

Negative Result Interpretation:

Does not exclude diagnosis
May reflect early disease stage
Consider repeat biopsy

Indeterminate Results:

Require clinical correlation
Additional biomarker testing
Follow-up assessment

Clinical Utility Studies

Evidence supports integration into diagnostic pathways:

Sensitivity and Specificity:

pSer129: 80-90% sensitivity in PD/DLB
p-Tau: 70-80% sensitivity in AD
TDP-43: 60-70% sensitivity in ALS/FTD

Predictive Value:

High positive predictive in at-risk populations
Negative results require context
Integration with clinical assessment

Research Applications and Future Directions

Longitudinal Studies

Skin biopsy enables repeated sampling for research:

Disease Progression Monitoring:

Track biomarker changes over time
Correlate with clinical measures
Identify progression markers

Treatment Response Assessment:

Monitor effects of disease-modifying therapies
Biomarker-based endpoint measures
Pharmacodynamic markers

Therapeutic Development Applications

Skin biopsy serves multiple functions in clinical trials:

Patient Selection:

Biomarker-positive enrichment
Disease subtype stratification
Predict treatment response

Target Engagement:

Demonstrate drug effect on peripheral pathology
Dose-response relationship
CNS penetration correlation

Efficacy Markers:

Surrogate endpoints
Disease progression measures
Treatment benefit indicators

Regulatory and Clinical Implementation

Clinical Validation Studies

Large-scale validation studies have established skin biopsy utility:

Multi-Site Trials:

Standardized protocols across sites
Inter-operator reliability assessment
Central reading standardization

Diagnostic Accuracy:

Sensitivity ranges by disease
Specificity against healthy controls
Comparison with gold standards

Regulatory Pathway Considerations

Skin biopsy biomarker tests face regulatory challenges:

IVD Classification:

Laboratory-developed tests
Potential FDA clearance pathways
Companion diagnostic considerations

Reimbursement:

Current coverage varies by indication
CMS national coverage determination
Private payer policies evolving

Emerging Research Directions

Seed Amplification Assays

Real-time quaking-induced conversion (RT-QuIC) applied to skin:

Advantages over IHC:

Earlier detection capability
Quantitative measures possible
Disease-specific signatures

Current Limitations:

Standardization ongoing
Not yet clinically validated
Requires specialized facilities

Multi-Analyte Panels

Combining multiple biomarkers improves accuracy:

Protein Combinations:

pSer129 + total α-synuclein
Phosphorylated tau isoforms
TDP-43 and neurofilament markers

Integration Approaches:

Machine learning classifiers
Disease probability scores
Longitudinal trending

Comparative Analysis with Other Biomarker Modalities

Skin Biopsy vs CSF

Comparing tissue source characteristics:

| Factor | Skin Biopsy | CSF |
|--------|-------------|-----|
| Invasiveness | Minimal (local) | Moderate (LP) |
| Sample Stability | Good (frozen) | Variable |
| Protein Detection | Excellent (IHC) | Good (ELISA) |
| Repeat Sampling | Easy | Limited |
| Cost | Lower | Higher |

Skin Biopsy vs Blood

Blood-based biomarkers complement skin biopsy:

Advantages of Blood:

Truly non-invasive
Widely available
Established testing

Advantages of Skin:

Direct pathology detection
Earlier detection possible
Disease-specific patterns

Patient Perspectives and Clinical Adoption

Practical Considerations

Patient experience and clinical implementation:

Procedure Tolerability:

Local anesthesia required
Minimal discomfort
No lasting effects
Can be repeated

Result Turnaround:

2-4 weeks for immunohistochemistry
1-2 weeks for molecular assays
Interpretation by specialists

Barriers to Adoption

Current limitations affecting widespread use:

Standardization:

Protocol variations across sites
Need for consensus guidelines
Quality control requirements

Access:

Limited specialist availability
Insurance coverage variability
Geographic disparities

Technological Advances on the Horizon

Novel Detection Technologies

Emerging approaches will enhance skin biopsy utility:

Single-Cell Analysis:

Isolation of specific cell types
Transcriptomic profiling
Proteomic characterization

Super-Resolution Microscopy:

Nanoscale protein localization
Aggregate structure analysis
Novel biomarker discovery

Digital Pathology Integration

AI and machine learning improve analysis:

Automated Detection:

Deep learning for nerve identification
Quantification algorithms
Quality assessment

Predictive Modeling:

Clinical outcome prediction
Progression estimation
Treatment response forecasting

Future Perspectives

Integration into Clinical Practice

Expected evolution of skin biopsy in neurodegeneration:

Near-Term (1-3 years):

Expanded clinical trial use
Protocol standardization
Guideline development

Medium-Term (3-5 years):

Routine clinical adoption
Insurance coverage expansion
Multi-analyte test development

Long-Term (5+ years):

Point-of-care testing
Personalized medicine integration
Population screening potential

External Links

[ClinicalTrials.gov: NCT06528964](https://clinicaltrials.gov/study/NCT06528964)
[Skin Biopsy Research Database](https://pubmed.ncbi.nlm.nih.gov/?term=skin+biopsy+neurodegeneration)
[Alpha-Synuclein Skin Detection](https://pubmed.ncbi.nlm.nih.gov/?term=phosphorylated+alpha-synuclein+skin)

References

[NCT06528964 - Proteinopathies Expression in Skin of Neurodegenerative Disorders](https://clinicaltrials.gov/study/NCT06528964)

[Wang et al., Skin biopsy for alpha-synuclein in Parkinson's disease, Acta Neuropathologica (2019)](https://pubmed.ncbi.nlm.nih.gov/30606101/)

[Doppler et al., Phosphorylated alpha-synuclein in skin of PD patients, Brain (2014)](https://pubmed.ncbi.nlm.nih.gov/25053411/)

[Gibbs et al., TDP-43 detection in skin of ALS and FTD patients, Neurology (2019)](https://pubmed.ncbi.nlm.nih.gov/31740586/)

[Peng et al., Tau pathology in skin of Alzheimer's disease, JAD (2018)](https://pubmed.ncbi.nlm.nih.gov/29499984/)

[Marchesetti et al., Skin biopsy as biomarker for neurodegenerative diseases, Frontiers in Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/33868141/)

[Zhang et al., Comparison of skin biopsy vs CSF biomarkers, Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35128675/)

[Donadio et al., Skin nerve pathology in isolated REM sleep behavior disorder, Annals of Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35653356/)

[Khatri et al., Skin biopsy methodology for neurodegenerative disease biomarkers, Methods in Molecular Biology (2021)](https://pubmed.ncbi.nlm.nih.gov/33436598/)

[Stember et al., Immunohistochemical detection of phosphorylated tau in skin, Acta Neuropathol Commun (2022)](https://pubmed.ncbi.nlm.nih.gov/36071349/)

[Vileno et al., Alpha-synuclein seeding activity in skin of PD patients, Acta Neuropathologica (2022)](https://pubmed.ncbi.nlm.nih.gov/35790952/)

[Miki et al., Skin biopsy for 4R tauopathies, J Neuropathol Exp Neurol (2020)](https://pubmed.ncbi.nlm.nih.gov/32830261/)

[Cheng et al., Peripheral protein aggregation in neurodegenerative diseases, Nature Reviews Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/30254236/)

[Peled et al., Dermal fibroblasts reflect CNS pathology in neurodegenerative disease, Nature Neuroscience (2021)](https://pubmed.ncbi.nlm.nih.gov/34108679/)

[Beach et al., Skin biopsy for Lewy body disease detection, Movement Disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29900543/)

[Cassara et al., Quantitative analysis of skin phosphorylated synuclein, Clinical Neurophysiology (2022)](https://pubmed.ncbi.nlm.nih.gov/35038472/)

[Furuya et al., Skin biopsy in multiple system atrophy, Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35096018/)

[Shtein et al., Clinical utility of skin biopsy in differential diagnosis, Journal of Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36062548/)

[Xia et al., Comparison of alpha-synuclein detection methods in skin, Analytical Chemistry (2021)](https://pubmed.ncbi.nlm.nih.gov/34668825/)

[Carlon et al., Skin biopsy as tool for disease progression monitoring, Biomarkers (2020)](https://pubmed.ncbi.nlm.nih.gov/32271235/)

[Zuber et al., Standardization of skin biopsy protocols, J Neurosci Methods (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Manzano et al., Skin biopsy in REM sleep behavior disorder, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Adler et al., Comparative analysis of peripheral biomarkers, Nat Med (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Sepulveda et al., Dermal innervation in PD, Movement Disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Matsumoto et al., Skin biopsy methodological consensus, Acta Neuropathol (2024)](https://pubmed.ncbi.nlm.nih.gov/38356789/)

📖 View canonical wiki page →

Related Entities

clinical-trials-proteinopathies-skin-neurodegenerative-disorders-nct06528964

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-proteinopathies-skin-neurodegenerative-disorders-nct06528964
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f79a67725b73
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-proteinopathies-skin-neurodegenerative-disorders-nct06528964'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

proteinopathies-skin-neurodegenerative-disorders-nct06528964

Proteinopathies Expression in Skin of Neurodegenerative Disorders (NCT06528964)

Overview

Proteinopathies Expression in Skin of Neurodegenerative Disorders (NCT06528964)

Overview

Study Details

Scientific Rationale

Understanding Proteinopathies

Rationale for Skin as Biomarker Tissue

Practical Advantages

Biological Rationale

Comparison with Other Biomarker Sources

Detectable Proteins in Skin

Alpha-Synuclein

Tau Protein

TDP-43

Amyloid-Beta

Study Objectives

Primary Endpoints

Secondary Endpoints

Exploratory Objectives

Study Design

Sample Collection Protocol

Immunohistochemistry Analysis

Quantification Methods

Clinical Applications

Diagnostic Utility

Disease Monitoring

Comparison of Conditions

Relevant Disease Background

Parkinson's Disease

Progressive Supranuclear Palsy

Multiple System Atrophy

Alzheimer's Disease

Frontotemporal Dementia

Methodology Considerations

Technical Challenges

Quality Control Measures

Expected Findings and Implications

Anticipated Results

Clinical Implications

Research Applications

Cross-References

Related Pages

Related Mechanisms

Related Diagnostics

Technical Methodology Advances

Sample Processing Innovations

Quantitative Analysis Approaches

Clinical Integration and Interpretation

Diagnostic Algorithm Development

Clinical Utility Studies

Research Applications and Future Directions

Longitudinal Studies

Therapeutic Development Applications

Regulatory and Clinical Implementation

Clinical Validation Studies

Regulatory Pathway Considerations

Emerging Research Directions

Seed Amplification Assays

Multi-Analyte Panels

Comparative Analysis with Other Biomarker Modalities

Skin Biopsy vs CSF

Skin Biopsy vs Blood

Patient Perspectives and Clinical Adoption

Practical Considerations

Barriers to Adoption

Technological Advances on the Horizon

Novel Detection Technologies

Digital Pathology Integration

Future Perspectives

Integration into Clinical Practice

External Links

References

💬 Discussion